Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Tara Lynn Kieffer Sells 2,283 Shares

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) insider Tara Lynn Kieffer sold 2,283 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $18,400.98. Following the completion of the sale, the insider now owns 29,305 shares in the company, valued at approximately $236,198.30. The trade was a 7.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock traded down $0.30 during trading on Tuesday, hitting $8.64. 429,363 shares of the stock traded hands, compared to its average volume of 209,776. Enanta Pharmaceuticals, Inc. has a 52-week low of $7.58 and a 52-week high of $17.80. The firm has a market capitalization of $183.08 million, a P/E ratio of -1.58 and a beta of 0.49. The firm’s fifty day moving average price is $10.51 and its 200-day moving average price is $12.04.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. Enanta Pharmaceuticals’s revenue was down 22.8% compared to the same quarter last year. During the same period last year, the business earned ($1.33) EPS. As a group, equities research analysts expect that Enanta Pharmaceuticals, Inc. will post -4.81 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ENTA. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Robert W. Baird reduced their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. Finally, JMP Securities restated a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $19.50.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new stake in Enanta Pharmaceuticals in the second quarter valued at approximately $35,000. US Bancorp DE grew its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at $122,000. Quest Partners LLC lifted its stake in Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 9,692 shares in the last quarter. Finally, Valence8 US LP purchased a new position in Enanta Pharmaceuticals during the 3rd quarter valued at about $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.